KP 1461

Known as: KP-1461, KP1461 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2013
012320062013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Treatment of HIV infection with conventional antiretroviral therapy (ART) is a lifelong challenge with significant long-term… (More)
Is this relevant?
2011
2011
BACKGROUND KP-1461 is a prodrug to KP-1212. KP-1212 is a viral mutagen designed to increase viral error rate. METHODS We… (More)
Is this relevant?
2011
2011
The deoxycytidine analog KP1212, and its prodrug KP1461, are prototypes of a new class of antiretroviral drugs designed to… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2011
2011
Background The deoxycytidine analog KP1212, and its prodrug KP1461, are prototypes of a new class of antiretroviral drugs… (More)
Is this relevant?
2010
2010
  • David Evans
  • BETA : bulletin of experimental treatments for…
  • 2010
The path of an experimental drug from the laboratory to U.S. Food and Drug Administration (FDA) approval is typically long, rocky… (More)
Is this relevant?
2010
2010
The deoxycytidine analog KP1212, and its prodrug KP1461, are prototypes of a new class of antiretroviral drugs designed to… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Review
2009
Review
2009
Over the past 20 years, nucleoside analogues have constituted an arsenal of choice in the fight against HIV, hepatitis B and C… (More)
Is this relevant?
2007
2007
KP-1461, an experimental HIV drug already in a phase II trial, works so differently from other antiretrovirals that at first… (More)
Is this relevant?
2006
2006
KP-1461 is a deoxycytidine analogue that is randomly inserted into HIV DNA by reverse transcriptase where it can cause base… (More)
Is this relevant?